Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854270 | 0.89 | HSD11B1 (0.41) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL29042564 | 0.78 | CTSK (0.49) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL26041859 | 0.77 | CTSK (0.48) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL21780374 | 0.77 | CTSK (0.47) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL25367681 | 0.76 | CTSK (0.47) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL147425 | 0.75 | CTSK (0.41) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL143514 | 0.75 | CTSK (0.41) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL142161 | 0.75 | CTSK (0.41) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL139448 | 0.75 | CTSK (0.41) | CTSKBTKHSD11B1CA1CA2 | |
| SCHEMBL19547113 | 0.74 | BTK (0.50) | CTSKBTKHSD11B1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CTSK 2772/4885BTK 3785/4885HSD11B1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.